• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Show Search
Home
EN / FR
  • LinkedIn
  • Twitter
Celyad Oncology

Celyad Oncology

  • About Us
    • Overview
    • Management Team
    • Board Of Directors
    • Scientific Advisory Board
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • TIM
      • shRNA
    • Manufacturing
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Contact Us
    • Careers

Cardio3 BioSciences Announces Secondary Placement …Newsroom Cardio3 BioSciences Announces Secondary Placement With New Institutional Investors

July 9, 2014 By Celyad

  • Six Swiss institutional funds purchase existing shares of the Company in a secondary placement

Mont?Saint?Guibert, Belgium,  ? Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of advanced regenerative therapies for heart disease, today announces the addition of six Swiss institutional funds to its shareholder base.

This transaction occurred aside of the market by exchange of shares between certain historical shareholders of the Company and Swiss professional investors. The transaction involved the sale of 141,800 shares at €43.5 each.The proportion of shares sold by the existing shareholders does not exceed 25% of their stake in the Company. The share capital and the number of shares of the Company remain unchanged after this secondary transaction.

Patrick Jeanmart, CFO of Cardio3 BioSciences, commented: “We are delighted to welcome new institutional funds to our shareholders. It reinforces our institutional shareholders base and has allowed us to manage to the benefit of all our shareholders the partial exit of some historical shareholders of the Company,”

Download press release(s)
Communiqué de presse
Press Release

Filed Under: Corporate, Regulated

Footer

  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.
Cookie Policy | Privacy Policy | Terms of Use

Our website uses cookies including analytics cookies to help improve it by collecting statistics on how visitors use our website. By clicking on "I accept", you allow us to place these analytics cookies. We also use cookies that are necessary for the good functioning of our website. You can find out more information about the cookies we use by visiting our Cookie Policy. I acceptI refuseCookie Policy